To begin trading February 17, 2004 under symbol MCU
WINNIPEG, Manitoba - (January 28, 2004) Medicure
Inc. (TSX:MPH), a cardiovascular drug discovery and development
company, is pleased to announce that it has received approval to
list its common shares of the Company on the American Stock Exchange®
(Amex®). Medicure shares are expected to commence trading on
the Amex on February 17, 2004 under the ticker symbol MCU.
"The approval to list our stock on the Amex is an important
milestone for the Company as it provides a second major trading
market for our stock, thereby increasing market awareness for our
shareholders," stated Albert D. Friesen, Ph.D., Medicure's
President and Chief Executive Officer. "This United States
listing will give Medicure increased visibility in the American
marketplace and makes the Company significantly more accessible
to U.S. investors.
"Our goal remains to increase exposure of our Company to institutional
and retail investors who would otherwise be restricted from purchasing
Medicure shares," Dr. Friesen added. "Broadening our investor
base by establishing ourselves in the USA market, is beneficial
to all shareholders."
About The American Stock Exchange
The American Stock Exchange®
(Amex®) is the only primary exchange that offers trading across
a full range of equities, options and exchange traded funds (ETFs),
including structured products and HOLDRSsm. In addition to its role
as a national equities market, the Amex is the pioneer of the ETF,
responsible for bringing the first domestic product to market in
1993. Leading the industry in ETF listings, the Amex lists 124 ETFs.
The Amex is also one of the largest options exchanges in the U.S.,
trading options on broad-based and sector indexes as well as domestic
and foreign stocks. For more information, please visit www.amex.com.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia, ischemic
reperfusion injury, and stroke. The cardiovascular and stroke market
is the largest pharmaceutical sector with annual global sales of
over US $70 billion.
The Company's second product candidate, MC-4232, is being targeted
for the treatment of hypertension, a common disorder in which blood
pressure remains abnormally high. Approximately 73% of the more
than 50 million adult Americans who have hypertension, are not adequately
treated.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
